Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics, a clinical-stage oncology company, is developing innovative therapies targeting oncogenic mutations, with promising initial Phase 2 results for its lead drug BDTX-1535 showing a 36% objective response rate (ORR) among evaluable patients in a relapsed/refractory non-small cell lung cancer (NSCLC) setting. The encouraging data, particularly the 42% ORR when focusing on patients with on-target resistance mutations, highlights the potential of BDTX-1535 to address unmet medical needs in patients with non-classical EGFR mutations, where current treatments are inadequate. Moreover, a significant portion of patients (74%) remained on treatment at the time of data cut, suggesting the potential for sustained efficacy as the company prepares for future data updates in 2025 that could further validate its market opportunities.

Bears say

Black Diamond Therapeutics Inc faces significant risks regarding its drug pipeline, particularly concerning the potential for negative efficacy data and an inadequate safety profile for its lead candidate, BDTX-1535, which could impact the overall therapeutic development. Adjustments to expense assumptions and commercialization timelines have led to a decrease in the projected valuation, reflecting an anticipated full-year net loss of $1.32 for 2025, indicating ongoing financial challenges. Additionally, the possibility of long-term dilution poses further concerns, potentially affecting shareholder value and the company's financial stability.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.